Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme and BD Technologies Strike Deal to Share Lab Space, Technology

NEW YORK, Sept. 10-Tranzyme has launched a research collaboration with BD Technologies, the two companies said today. Tranzyme also said today that it will also open a new lab for neurosensory disease research in BD Technologies' Research Triangle Park incubator.


For the research collaboration, Tranzyme will provide its gene transfer and protein expression technologies, which BD Technologies will use in specific cell lines for drug discovery, cell and tissue engineering.


BD has the right to market commercial products generated through this agreement, and will pay fees to Tranzyme for product sales. Tranzyme will have access to other BD Technologies intellectual property for its own drug development efforts in sensory system disease, as well as assistance in developing new collaborations with other divisions of BD.


Tranzyme expects that its new Research Triangle Park labs will allow the company to develop new collaborations with biotech companies in the area.


Tranzyme, which is based in Birmingham, Ala., focuses on genomics-based treatment for sensory diseases, neurodegenerative disease and viruses like HIV.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.